2015

Serglycin proteoglycan promotes progression and metastasis of triple-negative breast cancers

Cameron Johnstone  
*Peter MacCallum Cancer Ctr.*

Nathanial Harris  
*University of Wollongong, nlh28@uowmail.edu.au*

Marie Ranson  
*University of Wollongong, mranson@uow.edu.au*

Anil K. Rustgi  
*University of Pennsylvania*

Robin L. Anderson  
*Peter Maccallum Cancer Ctr.*

**Publication Details**
Serglycin proteoglycan promotes progression and metastasis of triple-negative breast cancers

Abstract
Abstract of a poster presentation at the AACR 106th Annual Meeting, 18-22 April, 2015, Philadelphia, PA.

Disciplines
Medicine and Health Sciences | Social and Behavioral Sciences

Publication Details
Serglycin proteoglycan promotes progression and metastasis of triple-negative breast cancers

Cameron N. Johnstone¹, Nathaniel Harris², Marie Ranson², Anil K. Rustgi³, and Robin L. Anderson¹

¹Peter MacCallum Cancer Ctr., East Melbourne, Australia; ²University of Wollongong, Wollongong, Australia; ³University of Pennsylvania, Philadelphia, PA.

Poster Presentation

Introduction
Triple-negative breast cancers have a propensity to metastasize and a poor outcome relative to other breast cancer subtypes. No molecularly targeted therapies exist for triple-negative disease and the standard of care for remains surgery followed by adjuvant radiotherapy and/or chemotherapy. Therefore, new therapies that target the molecular alterations present in triple-negative tumors are needed to either prevent metastatic dissemination or kill micrometastatic lesions at distant sites. The serglycin gene encodes a large secreted proteoglycan decorated with chondroitin sulfate modifications and expressed primarily by the hematopoietic system.¹ While serglycin was recently shown to be expressed by mammary epithelial cells², its role in breast oncogenesis is unclear.

Methods
Serglycin expression was analyzed by RNA-based (qRT-PCR) and protein-based (immunohistochemistry) methods³. Serglycin expression was specifically knocked down in triple-negative breast cancer lines (MDA-MB-231_HM4, SUM159) by shRNA technology using the pGIPZ lentiviral system. Genetically engineered cells were assessed in vitro using standard assays. Tumor growth and spontaneous metastasis to lung, liver and spleen was analyzed in vivo by orthotopic inoculation of cells into Nod.Scid.IL-2Rgamma-null (NSG)⁵ immuno-deficient mice.

Results
Serglycin was found to over-expressed in a subset of triple-negative breast cancers as well as in several metastatic triple-negative/claudin-low breast cancer cell lines including MDA-MB-231, SUM159 and Hs578T. Knockdown of serglycin was engineered in highly-metastatic MDA-MB-231_HM (231_HM) cells and in a metastatic variant of SUM159 cells. In vivo experiments showed that knockdown of serglycin reduced the growth rate of primary 231_HM tumours implanted in the mammary fat pads of mice. Moreover, following resection of the primary tumours, spontaneous metastasis to lung, liver and spleen was reduced in serglycin-depleted 231_HM cells.
Conclusions
The hematopoietic proteoglycan serglycin is over-expressed in a subset of triple-negative breast cancers and may represent a novel target for anti-cancer therapy.

References:


3. Li XJ, et al., Serglycin is a theranostic target in nasopharyngeal carcinoma that promotes metastasis. Cancer Res. 2011 71:3162-3172
